Headline: AbbVie Secures EC Approval for MAVIRET in Pediatric Hepatitis C Treatment

AbbVie (ABBV) announced on June 23, 2026, that the European Commission (EC) has approved MAVIRET (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C virus (HCV) infection in children aged 3 to less than 12 years. This approval expands the use of AbbVie's pan-genotypic, once-daily, ribavirin-free therapy to a younger pediatric population, addressing a significant unmet medical need. MAVIRET was previously approved in the European Union for adolescents and adults with chronic HCV infection. The recent EC decision is based on clinical data supporting the safety and efficacy of the treatment in this younger age group, providing an important new option for pediatric patients.